maximizing potential from Sanofi deal; starting a phase 3 for Novavax's combination proprietary flu plus COVID combo "very, very soon"; deals with third-party vaccine makers to enhance and develop ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy Jr. to run the Department of Health and Human Services. How do Sanofi ...

Back when Sanofi overhauled its branding in 2022, the French pharma absorbed the Genzyme unit—as well as its storied vaccines division Sanofi Pasteur—under the singular Sanofi corporate moniker.

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections. Novavax is working with the FDA to explore a pathway for ...

which affirms its commercial advantage and sets a milestone for Sanofi. This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in ...